Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis

  • Goki Suda
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Masaru Baba
    Department of Gastroenterology and Hepatology Japan Community Health Care Organization (JCHO) Hokkaido Hospital Hokkaido Japan
  • Yoshiya Yamamoto
    Department of Gastroenterology and Hepatology Hakodate City Hospital Hokkaido Japan
  • Takuya Sho
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Koji Ogawa
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Megumi Kimura
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Shunichi Hosoda
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Sonoe Yoshida
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Akinori Kubo
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Qingjie Fu
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Zijian Yang
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Yoshimasa Tokuchi
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Takashi Kitagataya
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Osamu Maehara
    Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences Hokkaido University Sapporo Japan
  • Shunsuke Ohnishi
    Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences Hokkaido University Sapporo Japan
  • Ren Yamada
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Masatsugu Ohara
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Naoki Kawagishi
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Mitsuteru Natsuizaka
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Masato Nakai
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Kenichi Morikawa
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Ken Furuya
    Department of Gastroenterology and Hepatology Japan Community Health Care Organization (JCHO) Hokkaido Hospital Hokkaido Japan
  • Kazuharu Suzuki
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
  • Takaaki Izumi
    Department of Gastroenterology and Hepatology Sapporo City General Hospital Hokkaido Japan
  • Takashi Meguro
    Department of Gastroenterology and Hepatology Hokkaido Gastroenterology Hospital Hokkaido Japan
  • Katsumi Terashita
    Department of Gastroenterology and Hepatology Japan Community Health Care Organization (JCHO) Sapporo Hokushin Hospital Hokkaido Japan
  • Jun Ito
    Department of Gastroenterology and Hepatology The Hokkaido Medical Center Hokkaido Japan
  • Tomoe Kobayashi
    Department of Gastroenterology and Hepatology Tomakomai City Hospital Hokkaido Japan
  • Izumi Tsunematsu
    Touei Naika Clinic Hokkaido Japan
  • Naoya Sakamoto
    Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan

抄録

<jats:title>Abstract</jats:title><jats:p>No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been reported. This multicenter prospective study enrolled HBV‐carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV‐reactivation and received TAF to prevent HBV reactivation‐related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation‐related hepatitis was evaluated at 6 and 12 months after initiating TAF. Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation‐related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous‐HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation‐related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. TAF could effectively prevent HBV reactivation and HBV reactivation‐related hepatitis.</jats:p>

収録刊行物

参考文献 (32)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ